Cambridge Antibody, Drug Royalty, Inwest Investments Ltd. deal

CAT extended to April 26 from March 27 its proposal to acquire DRI in a stock deal valuing DRI at C$3.10 per share (see BioCentury, March 18). In March, DRI's board withdrew its recommendation of acce...